News - 24 Feb `23Incyte wins EU nod for vitiligo cream Opzelura

New

Great news for the vitiligo community in the EU!

Incyte has just announced in a press-release that ruxolitinib cream (Opzelura™) has received a positive opinion from the European Medicines Agency (EMA) committee for the treatment of vitiligo with facial involvement.

The green light opens the fast track way for it to become the first ‘official’ vitiligo therapy available in the EU. Incyte has been eagerly awaiting approval in the EU ever since the it’s drug was registered by the US FDA in July 2022.

Opzelura, a 1.5% ruxolitinib cream, is a sister medication to Incyte's JAK inhibitor, Jakafi. It is used to treat nonsegmental vitiligo in patients ages 12 and older, with primarily facial involvement. The cream is meant to be applied twice a day on affected areas of up to 10% of the body’s surface area, and patients may need to use it for up to 24 weeks in order to see the best results.

More details

Vitiligo-Opzelura-pre-approval-EU

 



      FAQOther Questions

      • Are there any famous people with vitiligo?

        Many celebrities have dealt with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career. Here are a few courageous famous peo...

      • Shall I take vitamin D for my vitiligo?

        Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be ideal for mo...

      • Pyrostegia venusta as a folk medicine for vitiligo?

        Pyrostegia venusta, also known as “flame vine” or “cipó-de-são-joão,” is a neotropical evergreen vine native to Brazil. It thrives in fields, coastal areas, forest edges, and ro...